blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3946292

EP3946292 - ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  07.01.2022
Database last updated on 14.09.2024
FormerThe international publication has been made
Status updated on  03.10.2020
Most recent event   Tooltip28.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Essa Pharma, Inc.
999 West Broadway, Suite 720
Vancouver BC V5Z 1K5 / CA
For all designated states
The University of British Columbia
University Industry Liaison Office
103-6190 Agronomy Road
Vancouver, British Columbia V6T 1Z3 / CA
[2022/06]
Inventor(s)01 / ANDERSEN, Raymond John
4048 West 32nd Avenue
Vancouver, British Columbia V6S 1Z6 / CA
02 / ZHOU, Han-Jie
830 Argus Court
Foster City, California 94404 / US
[N/P]
Former [2022/06]01 / ANDERSEN, Raymond John
Vancouver, British Columbia V6S 1Z6 / CA
02 / ZHOU, Han-Jie
Foster City, California 94404 / US
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2022/06]
Application number, filing date20778151.927.03.2020
[2022/06]
WO2020US25542
Priority number, dateUS201962825387P28.03.2019         Original published format: US 201962825387 P
[2022/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020198711
Date:01.10.2020
Language:EN
[2020/40]
Type: A1 Application with search report 
No.:EP3946292
Date:09.02.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 01.10.2020 takes the place of the publication of the European patent application.
[2022/06]
Search report(s)International search report - published on:US01.10.2020
(Supplementary) European search report - dispatched on:EP18.04.2023
ClassificationIPC:A61K31/09, A61K31/10, A61K31/255, A61K51/04
[2022/06]
CPC:
A61K47/545 (EP,IL,KR); C07D417/14 (EP,IL,KR); A61K47/55 (EP,IL,KR,US);
A61K47/54 (US); A61P35/00 (KR); C07D207/08 (KR);
C07D231/38 (EP,IL,KR); C07D233/64 (EP,IL,KR); C07D233/88 (EP,IL,KR);
C07D237/20 (EP,IL); C07D239/42 (US); C07D239/47 (EP,IL,KR);
C07D239/48 (EP,IL,KR); C07D241/20 (EP,IL,KR); C07D261/08 (EP,IL,KR);
C07D261/10 (EP,IL,KR); C07D261/12 (EP,IL,KR); C07D261/14 (EP,IL,KR);
C07D263/32 (EP,IL,KR); C07D263/46 (EP,IL,KR); C07D263/48 (EP,IL,KR);
C07D271/113 (EP,IL,KR); C07D277/52 (EP,IL,KR); C07D307/66 (EP,IL,KR);
C07D401/04 (KR); C07D401/06 (KR); C07D401/12 (KR);
C07D401/14 (KR); C07D403/04 (KR); C07D403/06 (KR);
C07D413/12 (EP,IL,KR); C07D417/04 (KR); C07D417/12 (KR);
C07D471/04 (EP,IL,KR); C07D471/14 (EP,IL); C07D487/10 (KR);
C07D491/052 (EP,IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/06]
TitleGerman:ANDROGENREZEPTOR-MODULATOREN UND VERFAHREN ZUR VERWENDUNG ALS GEGEN PROTEOLYSE GERICHTETE CHIMÄRE LIGANDEN[2022/06]
English:ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS[2022/06]
French:MODULATEURS DU RÉCEPTEUR DES ANDROGÈNES ET MÉTHODES ASSOCIÉES À UTILISER EN TANT QUE LIGANDS CHIMÈRES CIBLANT LA PROTÉOLYSE[2022/06]
Entry into regional phase25.10.2021National basic fee paid 
25.10.2021Search fee paid 
25.10.2021Designation fee(s) paid 
25.10.2021Examination fee paid 
Examination procedure25.10.2021Examination requested  [2022/06]
16.11.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
28.03.2022Renewal fee patent year 03
27.03.2023Renewal fee patent year 04
27.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[YDA]WO2016112455  (BRITISH COLUMBIA CANCER AGENCY [CA], et al) [YD] 1-17,19-21 * Table 1 on pages 31-70 * * claims 15, 17, 22-26 *[A] 18;
 [YA]US2018228907  (CREW ANDREW P [US], et al) [Y] 1-17,19-21 * claims 2, 4-16, 19, 25, 28-30 * * paragraphs [0376] - [0520] * [A] 18;
 [YDA]  - NEKLESA TAAVI K ET AL, "ARV-330: Androgen receptor PROTAC degrader for prostate cancer. | Journal of Clinical Oncology", JOURNAL OF CLINICAL ONCOLOGY, vol. 34, no. 2_suppl, doi:10.1200/jco.2016.34.2_suppl.267, (20160110), page 267, URL: https://ascopubs.org/doi/10.1200/jco.2016.34.2_suppl.267, XP093036168 [YD] 1-17,19-21 * the whole document * [A] 18

DOI:   http://dx.doi.org/10.1200/jco.2016.34.2_suppl.267
 [YA]  - SHANSHAN GU ET AL, "PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery", BIOESSAYS, JOHN WILEY & SONS LTD, GB, (20180223), vol. 40, no. 4, doi:10.1002/BIES.201700247, ISSN 0265-9247, page n/a, XP071526852 [Y] 1-17,19-21 * section 5.2 * * figure 5A * [A] 18

DOI:   http://dx.doi.org/10.1002/bies.201700247
International search[A]US2015210681  (BOURQUE ELYSE [US], et al) [A] 1-2, 7, 11 * , entire document, especially: (para [1111], 1-(4'-(3-methoxypropoxy)-[1,1'-biphenyl]-4-yl)cyclopropanecarboxylic acid). *;
 [A]WO2016141458  (BRITISH COLUMBIA CANCER AGENCY BRANCH [CA], et al) [A] 1-2, 7, 11 * , entire document, especially: abstract; pg 45, Example 1, Formula III. *;
 [A]  - RAINA et al., "PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer", PNAS, (20160000), vol. 113, no. 26, doi:10.1073/pnas.1521738113, pages 7124 - 7129, XP055422055 [A] 1-2, 7, 11 * , entire document, especially: pg 7124, col 1, para 2; pg 7124, col 2, para 2. *

DOI:   http://dx.doi.org/10.1073/pnas.1521738113
 [A]  - QIN et al., "Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression", J Med Chem., (20180000), vol. 61, no. 15, doi:10.1021/acs.jmedchem.8b00506, pages 6685 - 6704, XP055522768 [A] 1-2, 7, 11 * , entire document. *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.8b00506
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.